MX2023005446A - Particulas virales modificadas para terapia genica. - Google Patents
Particulas virales modificadas para terapia genica.Info
- Publication number
- MX2023005446A MX2023005446A MX2023005446A MX2023005446A MX2023005446A MX 2023005446 A MX2023005446 A MX 2023005446A MX 2023005446 A MX2023005446 A MX 2023005446A MX 2023005446 A MX2023005446 A MX 2023005446A MX 2023005446 A MX2023005446 A MX 2023005446A
- Authority
- MX
- Mexico
- Prior art keywords
- modified viral
- gene therapy
- surface modified
- viral capsids
- viral particles
- Prior art date
Links
- 230000003612 virological effect Effects 0.000 title abstract 5
- 238000001415 gene therapy Methods 0.000 title abstract 2
- 239000002245 particle Substances 0.000 title 1
- 210000000234 capsid Anatomy 0.000 abstract 4
- 210000002845 virion Anatomy 0.000 abstract 2
- 230000005856 abnormality Effects 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Esta invención se refiere a nuevas cápsides virales modificadas en superficie y viriones recombinantes que comprenden las mismas. Además, esta invención se refiere a compuestos intermedios para la preparación de cápsides virales modificadas en superficie. Las cápsides virales modificadas en superficie se diseñan para administrar de manera selectiva y/o más eficientemente la terapia génica. La cápside viral modificada en superficie, cuando se incorpora en un virión recombinante, se puede utilizar para tratar un padecimiento que se caracteriza por anomalía genética.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063112457P | 2020-11-11 | 2020-11-11 | |
PCT/EP2021/081424 WO2022101363A1 (en) | 2020-11-11 | 2021-11-11 | Modified viral particles for gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023005446A true MX2023005446A (es) | 2023-07-18 |
Family
ID=78770604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023005446A MX2023005446A (es) | 2020-11-11 | 2021-11-11 | Particulas virales modificadas para terapia genica. |
Country Status (11)
Country | Link |
---|---|
US (1) | US11938196B2 (es) |
EP (1) | EP4244209A1 (es) |
JP (1) | JP2023548432A (es) |
KR (1) | KR20230107619A (es) |
CN (1) | CN116648448A (es) |
AU (1) | AU2021378075A1 (es) |
CA (1) | CA3201533A1 (es) |
IL (1) | IL302741A (es) |
MX (1) | MX2023005446A (es) |
TW (1) | TW202233584A (es) |
WO (1) | WO2022101363A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024044691A2 (en) * | 2022-08-25 | 2024-02-29 | The Trustees Of Indiana University | Modified aav vectors for gene therapy |
WO2024131982A1 (zh) * | 2022-12-23 | 2024-06-27 | 北京大学宁波海洋药物研究院 | 衣壳蛋白-抗体偶联物、修饰的病毒、药物组合和用途 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
TR201906398T4 (tr) | 2009-04-30 | 2019-05-21 | Univ Pennsylvania | Salgı bezleriyle ilişkili virüs yapılarını içeren iletken hava yolu hücrelerinin hedeflenmesine yönelik bileşimler. |
MX370265B (es) | 2012-05-25 | 2019-12-09 | Cellectis | Métodos para manipular por ingeniería genética célula t alogénica y resistente a inmunosupresores para inmunoterapia. |
CA2917018A1 (en) | 2013-05-21 | 2014-12-04 | University Of Florida Research Foundation, Inc. | Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer |
ES2645393T3 (es) | 2013-05-29 | 2017-12-05 | Cellectis | Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN |
PL3459965T3 (pl) | 2013-10-11 | 2021-07-26 | Massachusetts Eye & Ear Infirmary | Sposoby przewidywania sekwencji wirusa-przodka i ich zastosowania |
CN104592364B (zh) | 2013-10-30 | 2018-05-01 | 北京大学 | 定点突变和定点修饰的腺相关病毒、其制备方法及应用 |
EP3097080A1 (en) * | 2014-01-24 | 2016-11-30 | SynAffix B.V. | Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne |
GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
DK3872085T5 (da) | 2015-07-30 | 2024-08-12 | Massachusetts Eye & Ear Infirmary | Stam-virussekvenser og anvendelser heraf |
KR102423442B1 (ko) | 2015-12-11 | 2022-07-20 | 캘리포니아 인스티튜트 오브 테크놀로지 | 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드 |
WO2017189963A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
RU2725286C2 (ru) | 2016-05-13 | 2020-06-30 | 4Д Молекьюлар Терапьютикс Инк. | Варианты капсидов аденоассоциированного вируса и способы их применения |
SI3589730T1 (sl) | 2017-02-28 | 2024-04-30 | The Trustees Of The University Of Pennsylvania | Adeno-povezan virus (AAV) clade F vektor in njihova uporaba |
RS65569B1 (sr) | 2017-06-27 | 2024-06-28 | Regeneron Pharma | Rekombinantni virusni vektori modifikovani tropizmom i njihove upotrebe za ciljano uvođenje genetičkog materijala u humane ćelije |
EP3461836A1 (en) | 2017-09-28 | 2019-04-03 | Universität zu Köln | Mutated adeno-associated viral capsid proteins for chemical coupling of ligands, nanoparticles or drugs via thioether binding and production method thereof |
CN112040988A (zh) | 2018-04-27 | 2020-12-04 | 海德堡大学 | 修饰的aav衣壳多肽用于治疗肌肉疾病 |
CA3100006A1 (en) | 2018-05-11 | 2019-11-14 | Massachusetts Eye And Ear Infirmary | Altering tissue tropism of adeno-associated viruses |
CA3114199A1 (en) | 2018-09-26 | 2020-04-02 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
MX2021013267A (es) | 2019-04-29 | 2021-11-17 | Univ Pennsylvania | Nuevas capsides de aav y composiciones que las contienen. |
EP3736330A1 (en) | 2019-05-08 | 2020-11-11 | European Molecular Biology Laboratory | Modified adeno-associated virus (aav) particles for gene therapy |
AU2020368539A1 (en) | 2019-10-16 | 2022-04-28 | Massachusetts Institute Of Technology | Engineered muscle targeting compositions |
-
2021
- 2021-11-11 EP EP21814723.9A patent/EP4244209A1/en active Pending
- 2021-11-11 KR KR1020237019366A patent/KR20230107619A/ko unknown
- 2021-11-11 TW TW110142094A patent/TW202233584A/zh unknown
- 2021-11-11 CN CN202180090086.XA patent/CN116648448A/zh active Pending
- 2021-11-11 IL IL302741A patent/IL302741A/en unknown
- 2021-11-11 WO PCT/EP2021/081424 patent/WO2022101363A1/en active Application Filing
- 2021-11-11 AU AU2021378075A patent/AU2021378075A1/en active Pending
- 2021-11-11 JP JP2023550717A patent/JP2023548432A/ja active Pending
- 2021-11-11 CA CA3201533A patent/CA3201533A1/en active Pending
- 2021-11-11 MX MX2023005446A patent/MX2023005446A/es unknown
-
2023
- 2023-05-11 US US18/316,191 patent/US11938196B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2021378075A1 (en) | 2023-06-22 |
EP4244209A1 (en) | 2023-09-20 |
TW202233584A (zh) | 2022-09-01 |
JP2023548432A (ja) | 2023-11-16 |
KR20230107619A (ko) | 2023-07-17 |
US20230338578A1 (en) | 2023-10-26 |
WO2022101363A1 (en) | 2022-05-19 |
CN116648448A (zh) | 2023-08-25 |
US11938196B2 (en) | 2024-03-26 |
IL302741A (en) | 2023-07-01 |
CA3201533A1 (en) | 2022-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023005446A (es) | Particulas virales modificadas para terapia genica. | |
EP2547765A4 (en) | BETA-PROPIOLACTONE FOR INACTIVATING VIRUSES IN PANCREATIC PHARMACEUTICAL ENZYMATIC PREPARATIONS | |
Schweneker et al. | The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulence | |
EP4378487A3 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
JP2012526532A (ja) | 不死化鳥類細胞系およびその用途 | |
EA201001202A1 (ru) | Атенуированные онколитические парамиксовирусы, кодирующие птичьи цитокины | |
MX2021012311A (es) | Variantes de capsides de aav para liberacion intravitrea. | |
MX2019008105A (es) | Virus. | |
EA201991806A1 (ru) | Опухоль-селективные мутанты tata-бокса и caat-бокса | |
Yi et al. | Enhanced production of enveloped viruses in BST‐2‐deficient cell lines | |
MX2021001292A (es) | Metodos para la modificacion genica de celulas hematopoyeticas. | |
MX2023007411A (es) | Composiciones de protoparvovirus y tetraparvovirus y metodos para terapia genica. | |
Yamada et al. | Establishment and characterization of transformed goat primary cells by expression of simian virus 40 large T antigen for orf virus propagations | |
MX2023001137A (es) | Beta-glucocerebrosidasa mutada con estabilidad mejorada. | |
WO2022187148A3 (en) | Multi-armed myxoma virus | |
MX2021013597A (es) | El polipeptido ix adenoviral aumenta la productividad y la infectividad del vector adenoviral de terapia genica. | |
MX2023000995A (es) | Vector de genoterapia para eef1a2 y usos del mismo. | |
Zhang et al. | Recombinant interferon-γ lentivirus co-infection inhibits adenovirus replication ex vivo | |
MX2019012106A (es) | Metodo de sintesis y uso de bionanoparticulas con actividad asparaginasa utilizando capsides virales para tratar enfermedades asociadas con la dependencia de asparagina. | |
MX2023003994A (es) | Construcciones de acido nucleico, vectores virales y particulas virales. | |
KR20030081338A (ko) | 종양 세포에서 고효율로 종양 세포 혈관형성 억제인자를발현시키는 바이러스 및 이의 용도 | |
WO2024137869A3 (en) | Stem cells for delivery of oncolytic viruses | |
WO2023154763A3 (en) | Adeno-associated viral vector for glut1 expression and uses thereof | |
WO2022221421A3 (en) | Aav compositions with high brain expression for treating mucopolysaccharidosis ii | |
Mokhtari et al. | Developing an Antiviral Drug Screening System for Anti-Bovine Viral Diarrhea Virus (BVDV) Therapies |